GYNECOLOGIC CANCER: Edited by Gottfried E. KonecnyAdvances in antibody-drug conjugates for gynecologic malignanciesTymon-Rosario, Joana; Gorman, Megana; Richardson, Debra L.b; Washington, Christinab; Santin, Alessandro D.c Author Information aDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New Hyde Park, New York 11040 bDepartment of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, Connecticut 06520 cStephenson Cancer Center at the University of Oklahoma Health Sciences Center, 800 N.E. 10th Street, Oklahoma City, Oklahoma 73104, USA Correspondence to Alessandro D. Santin, MD, Department of Obstetrics, Gynecology, and Reproductive Sciences, Co-Chief Gynecologic Oncology, Yale School of Medicine, LSOG Bld. Room 305, 333 Cedar Street, PO Box 208063, New Haven, CT, 06520-8063, USA. Tel: +203 737 4450; fax: +203 737 4339; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology 35(1):p 6-14, February 2023. | DOI: 10.1097/GCO.0000000000000838 Buy Metrics Abstract Purpose of review Antibody-drug conjugates (ADCs) represent a new class of drugs that combine a surface receptor-targeting antibody linked to a cytotoxic molecule delivering the potent cytotoxic payload directly to tumor cells. This review summarizes the current literature demonstrating their use in the treatment of gynecologic malignancies. Recent findings Tisotumab vedotin is the first U.S. Food and Drug Administration (FDA) approved ADC for the treatment of gynecologic cancers. While in the phase 3 randomized controlled trial in platinum resistant ovarian cancer patients, FORWARD 1, mirvetuximab did not meet its primary endpoint of progression-free survival. But we await more recent data from the two ongoing phase 3 trials of mirvetuximab in recurrent ovarian cancer patients. HER2/neu, Napi2b, mesothelin, and human trophoblast cell-surface marker (Trop-2) overexpression have also been exploited as excellent targets by novel ADCs in multiple tumors including ovarian, endometrial, and cervical cancers. Summary Current evidence strongly supports the use of ADCs and ongoing clinical trials will provide further information into the potential of making these drugs part of current standard practice allowing patients to be treated with a higher level of personalized cancer care. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.